Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8. (Q38576208)

4 September 2017

title

Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8. (English)

1 reference

4 September 2017

1 reference

1 reference

Ichiro Kurane

1 reference

4 September 2017

Tomoya Saito

0 references

Yasuhiro Kanatani

0 references

Akiko Eto

1 reference

4 September 2017

Hiroyuki Yokote

series ordinal

1 reference

4 September 2017

language of work or name

English

0 references

publication date

25 August 2015

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

page(s)

6106-6111

1 reference

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Smallpox vaccine and its stockpile in 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Smallpox vaccine safety is dependent on T cells and not B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

LC16m8: an attenuated smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Third-Generation Smallpox Vaccines: Challenges in the Absence of Clinical Smallpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Smallpox vaccines: targets of protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Duration of antiviral immunity after smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Immunity and immunological memory following smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Immunity from smallpox vaccine persists for decades: a longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Antibody responses to vaccinia membrane proteins after smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Golgi network targeting and plasma membrane internalization signals in vaccinia virus B5R envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Serological responses in humans to the smallpox vaccine LC16m8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

The formation and function of extracellular enveloped vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Proteome-wide analysis of the serological response to vaccinia and smallpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Analysis of the human immune response to vaccinia by use of a novel protein microarray suggests that antibodies recognize less than 10% of the total viral proteome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Capturing the natural diversity of the human antibody response against vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.111

10.1016/J.VACCINE.2015.07.111

7 January 2021

Identifiers

DOI

1 reference

4 September 2017

1 reference